課程名稱 |
藥物流行病學 Pharmacoepidemiology |
開課學期 |
107-2 |
授課對象 |
公共衛生學院 流行病學與預防醫學研究所 |
授課教師 |
陳建煒 |
課號 |
EPM7166 |
課程識別碼 |
849 M0610 |
班次 |
|
學分 |
2.0 |
全/半年 |
半年 |
必/選修 |
選修 |
上課時間 |
星期一6,7(13:20~15:10) |
上課地點 |
公衛210 |
備註 |
與張家勳合授 總人數上限:30人 |
Ceiba 課程網頁 |
http://ceiba.ntu.edu.tw/1072EPM7166_PE |
課程簡介影片 |
|
核心能力關聯 |
核心能力與課程規劃關聯圖 |
課程大綱
|
為確保您我的權利,請尊重智慧財產權及不得非法影印
|
課程概述 |
This is an introductory course on pharmacoepidemiology. How the principles of modern epidemiology methods are applied to evaluate safety, effectiveness, and utilization patterns of medical products (drugs, vaccines, and medical devices) will be discussed. Examples of descriptive epidemiology studies, cohort studies, case control studies, intervention studies, and meta-analysis will be drawn from recent literature to illustrate the application of relevant methods and the challenges in post-marketing medical product assessment. Perspectives from research institutions, medical product manufacturers, and regulatory agencies will be presented. Related topics, including therapeutic risk management, safety signal detection and refinement, data sources and ethics considerations, will be discussed. Advanced methodology, such as that utilized to address confounding by indication and misclassification will be briefly introduced. |
課程目標 |
To know how the principles of modern epidemiology methods are applied to evaluate safety, effectiveness, and utilization patterns of medical products (drugs, vaccines, and medical devices). |
課程要求 |
Attend lectures, class presentation, homework, and a term paper |
預期每週課後學習時數 |
|
Office Hours |
|
參考書目 |
peer-reviewed research articles, commentaries, and FDA & EMA regulatory documents
Optional textbook Strom, Kimmel, & Hennessy (eds). Textbook of
Pharmacoepidemiology, 2nd Edition. Sussex: Wiley, 2013
FDA Guidance for Industry -- Good Pharmacovigilance Practices and
Pharmacoepidemiologic Assessment.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf
EMA Guideline on good pharmacovigilance practices (GVP) Module VIII –
Post-authorisation safety studies
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129137.pdf
Guidelines for Good Pharmacoepidemiology Practices (GPP) --
http://www.pharmacoepi.org/resources/guidelines_08027.cfm |
指定閱讀 |
待補 |
評量方式 (僅供參考) |
|
週次 |
日期 |
單元主題 |
第1週 |
2/18 |
Course overview, introduction |
第2週 |
2/25 |
Medical product development and product life cycle
Real World Evidence
|
第3週 |
3/04 |
Guest speaker 黃薇伊組長 |
第4週 |
3/11 |
Commonly used research methods in pharmacoepidemiology |
第5週 |
3/18 |
Cohort studies |
第6週 |
3/25 |
Case-controls studies |
第7週 |
4/01 |
Case-crossover studies |
第8週 |
4/08 |
Self-controlled case series
Meta-analysis for safety assessment
|
第9週 |
4/15 |
Comorbidity measures and control for confounding (I) |
第10週 |
4/22 |
Control for confounding (II) and hierarchy of evidence |
第11週 |
4/29 |
Safety surveillance, safety signal detection & refinement |
第12週 |
5/06 |
Health data and related ethical considerations |
第13週 |
5/13 |
Drug utilization studies
Time series analysis
|
第14週 |
5/20 |
Pharmacogenomic
Epidemiology in medical product development
|
第15週 |
5/27 |
Regulatory decisions and therapeutic risk management |
第16週 |
6/03 |
Benefit-Risk assessment
Pragmatic trials
|
|